Chemkart , a leading player in the nutraceutical raw materials and functional ingredients sector, has reported a strong financial performance for the half year ended September 30, 2025. The company, which recently completed its Initial Public Offering (IPO), has shown significant growth in revenue and profitability.

Financial Highlights

Chemkart reported a consolidated revenue from operations of Rs. 10,322.56 lakhs for the half year ended September 30, 2025, representing a robust growth of 14.5% compared to Rs. 9,015.24 lakhs in the previous half year. The company's profit after tax stood at Rs. 1,015.26 lakhs, up from Rs. 889.57 lakhs in the prior period, marking a 14.1% increase.

Successful IPO and Strengthened Financial Position

During the period, Chemkart successfully completed its Initial Public Offering, raising Rs. 6,448 lakhs through a fresh issue of 26,00,000 equity shares at Rs. 248 per share. The company's shares were listed on the SME Platform of BSE on July 10, 2025.

The IPO has significantly strengthened Chemkart's financial position:

• Post-IPO net worth increased to Rs. 12,022.41 lakhs
• Cash and cash equivalents rose to Rs. 4,374.58 lakhs from Rs. 283.13 lakhs

Utilization of IPO Proceeds

The company has outlined the following utilization of IPO proceeds:

Operational Highlights

Chemkart operates through two wholly-owned subsidiaries:

1. Easy Raw Materials Private Limited (ERMPL): Currently developing a manufacturing facility at JNPA SEZ, Navi Mumbai, focused on finished formulations.
2. Vinstar Biotech Private Limited (VBPL): Engaged in custom formulation and contract development.

The ERMPL facility at JNPA SEZ is progressing well, with foundation and piling works underway. This project is expected to enable in-house formulation, packaging, and export operations, aligning with the company's IPO objectives.

Management Commentary

Mr. Ankit Shailesh Mehta, Chairman and Managing Director of Chemkart, stated, "We are pleased with our performance in the first half of FY26. The successful IPO has provided us with the resources to accelerate our growth plans, particularly in expanding our manufacturing capabilities. Our focus remains on establishing Chemkart as a fully integrated, export-driven nutraceutical enterprise by FY 2026-27, with scalable manufacturing, strong R&D integration, and consistent shareholder value creation."

Future Outlook

Chemkart is positioning itself as a B2B nutraceutical solutions platform, integrating sourcing, manufacturing, and formulation capabilities. The company's strategic focus areas include:

• Advancing ERMPL's SEZ facility construction
• Expanding VBPL's R&D and branded products
• Enhancing global partnerships and export growth

With a strong financial foundation and clear strategic direction, Chemkart appears well-positioned for continued growth in the nutraceutical and functional ingredients market.

Chemkart India Limited, a leading B2B supplier of raw ingredients for nutritional, sports, and health supplements, has submitted an investor presentation to the Bombay Stock Exchange (BSE) highlighting its strong financial performance and ambitious growth plans. The company, established in 2015 and headquartered in Mumbai, has showcased impressive financial results and announced a significant expansion of its manufacturing capabilities.

Financial Performance

Chemkart India has reported substantial growth in its financial metrics:

The company's Return on Equity (ROE) and Return on Capital Employed (ROCE) for FY25 stood at 46% and 49% respectively, indicating strong operational efficiency and profitability.

Operational Highlights

Chemkart India operates with a diverse portfolio of over 150 ingredients across more than 10 product categories. The company serves over 500 clients and maintains a 30,000 sq.ft warehouse facility in Bhiwandi, Maharashtra. This facility is equipped for blending, grinding, packing, labelling, and sealing operations, with a daily grinding capacity of 1.8 MT and a blending capacity of 1.5 MT.

New Manufacturing Facility

In a significant move towards vertical integration and expansion, Chemkart India has announced the construction of a greenfield nutraceutical Contract Development and Manufacturing Organization (CDMO) facility. This project will be executed through its subsidiary, Easy Raw Materials Private Limited, at the JNPT Special Economic Zone (SEZ) in Maharashtra. Key features of the new facility include:

• 4,120 sq.m plot leased for 60 years at JNPA SEZ, Raigad
• Integrated CDMO operations for formulation, packaging, and global dispatch
• Dosage formats including tablets, capsules, jars, and sachets
• Focus on novel technologies such as microencapsulation, liposomal delivery systems, and enhanced bioavailability formats
• Modern infrastructure including QC labs, warehousing, and sustainability features

The facility is expected to be operational by FY27 and is strategically positioned near India's largest container port, offering seamless access to global markets and duty-free benefits under SEZ policy.

Market Focus and Future Outlook

While Chemkart India currently derives 99.25% of its revenue from the domestic market, the new SEZ-based facility is primarily aimed at export markets. This move aligns with the company's vision to become a global leader in end-to-end CDMO solutions and trusted distribution of food, health, and specialty ingredients.

The company is well-positioned to capitalize on India's growing nutraceutical market, which is projected to reach USD 76 billion by 2033, growing at a CAGR of 10%. Chemkart India's focus on high-margin specialty and performance chemicals, coupled with its expansion into CDMO operations, sets the stage for scalable growth and potential market leadership.

Chemkart India Limited's strategic initiatives, including its new manufacturing facility and focus on export markets, demonstrate the company's commitment to long-term growth and its ambition to play a significant role in India's evolving nutraceutical industry.